1. 1H-Indazole-3-carboxylic Acid (CAS 4498-67-3)
This core scaffold has been extensively adopted by major pharmaceutical companies including Novartis, Takeda, Roche, AbbVie, and Theravance for drug discovery programs. Key patent applications include:
Kinase Inhibition (AbbVie, US9163007B2)
AbbVie’s patent describes indazole-3-carboxylic acid derivatives as potent kinase inhibitors targeting multiple signaling pathways relevant to oncology.
5-HT4 Receptor Agonism (Theravance, US7674908B2)
Theravance has developed indazole-based 5-HT4 receptor agonists for gastrointestinal motility disorders.
Wnt/β-Catenin Pathway Modulation (Samumed, RU2770613C2; JP6457459B2)
Samumed’s patents cover indazole-3-carboxamide compounds as inhibitors of the Wnt/β-catenin signaling pathway, with applications in tendinopathy, fibrotic diseases, and oncology.
Additional Applications:
- ENaC inhibition (Novartis, US9643983B2)
- Nicotinic acetylcholine receptor ligands (Memory Pharmaceuticals, US8008481B2)
- GSK-3β inhibition (A.C.R.A.F., US10160746B2)
- CBP/EP300 inhibition (Genentech, CN107108512B)
- Complement pathway modulation (Novartis, US9815819B2)
2. 5-Bromo-1H-indazole-3-carboxylic Acid (CAS 1077-94-7)
The 5-bromo derivative offers enhanced synthetic versatility as a halogenated building block. The bromine atom enables further functionalization via Suzuki, Sonogashira, and Buchwald-Hartwig cross-coupling reactions.
GSK-3β Inhibitors (A.C.R.A.F., US10160746B2)
The 5-bromo substituent optimizes binding affinity at the ATP-binding site of glycogen synthase kinase 3 beta, relevant for neurodegenerative diseases and mood disorders.
CBP/EP300 Inhibitors (Genentech, CN107108512B; CN109476641B)
Halogenated indazole scaffolds for selective inhibition of CBP/EP300 bromodomains — a novel approach to cancer therapy.
Kinase Modulation (Plexxikon, ES2899581T3)
Plexxikon’s kinase modulation platform incorporates the 5-bromoindazole core for selective kinase targeting.
Top patent assignees in this space include Novartis AG, Merck Sharp & Dohme, F. Hoffmann-La Roche, and Bristol-Myers Squibb.
3. MDMB-INACA (CAS 2709672-58-0)
MDMB-INACA is an indazole-3-carboxamide synthetic cannabinoid receptor modulator. Patent WO2022217147A1 (Rosenfeld) describes its application in transdermal cannabinoid formulations for improved cutaneous permeation. The indazole-3-carboxamide core provides selectivity for cannabinoid receptors CB1 and CB2, making it a valuable pharmacological reference standard for forensic toxicology research.
4. 5-Bromopent-1-ene (CAS 1119-51-3)
This bifunctional C5 building block features a terminal alkene and primary bromide. The alkene participates in radical addition, hydroboration, epoxidation, and olefin metathesis. The bromide serves as an electrophile for nucleophilic substitution and cross-coupling reactions. Widely used in pharmaceutical intermediate synthesis and natural product total synthesis.
Summary
These indazole-based building blocks have been validated by top-tier pharmaceutical companies across multiple therapeutic areas including oncology, neurodegeneration, metabolic disorders, and inflammation. Their structural versatility makes them indispensable tools for medicinal chemistry programs.